Predicting ERCP procedure time – the SWedish Estimation of ERCP Time (SWEET) tool

Abstract

Background: The duration of an endoscopic retrograde cholangiopancreatography (ERCP) is influenced by a multitude of factors. The aim of this study was to describe the factors influencing ERCP time and to create a tool for preintervention estimation of ERCP time.

Methods: Data from 74 248 ERCPs performed from 2010 to 2019 were extracted from the Swedish National Quality Registry (GallRiks) to identify variables predictive for ERCP time using linear regression analyses and root mean squared error (RMSE) as a loss function. Ten variables were combined to create an estimation tool for ERCP duration. The tool was externally validated using 9472 ERCPs from 2020 to 2021.

Results: Mean (SD) ERCP time was 36.8 (25.3) minutes. Indications with the strongest influence on ERCP time were primary sclerosing cholangitis and chronic pancreatitis. Hilar and intrahepatic biliary strictures and interventions on the pancreatic duct were the anatomic features that most strongly affected ERCP time. The procedure steps with most influence were intraductal endoscopy, lithotripsy, dilation, and papillectomy. Based on these results, we built and validated the Swedish Estimation of ERCP Time (SWEET) tool, which is based on a 10-factor scoring system (e.g. 5 minutes for bile duct cannulation and 15 minutes for pancreatic duct cannulation) and predicted ERCP time with an average difference between actual and predicted duration of 17.5 minutes during external validation.

Conclusions: Based on new insights into the factors affecting ERCP time, we created the SWEET tool, the first specific tool for preintervention estimation of ERCP time, which is easy-to-apply in everyday clinical practice, to guide efficient ERCP scheduling.

Publication History

Received: 13 April 2023

Accepted after revision: 03 July 2024

Article published online:
07 August 2024

• References

• 1 McCune WS, Shorb PE, Moscovitz H. Endoscopic cannulation of the ampulla of Vater: a preliminary report. Ann Surg 1968; 167: 752-756 DOI: 10.1097/00000658-196805000-00013. (PMID: 5646296)
• 2 Soreide JA, Karlsen LN, Sandblom G. et al. Endoscopic retrograde cholangiopancreatography (ERCP): lessons learned from population-based national registries: a systematic review. Surg Endosc 2019; 33: 1731-1748
• 3 Williams EJ, Ogollah R, Thomas P. et al. What predicts failed cannulation and therapy at ERCP? Results of a large-scale multicenter analysis. Endoscopy 2012; 44: 674-683
• 4 Voiosu TA, Bengus A, Bronswijk M. et al. A simple clinical score to stratify the risk of procedure-related adverse events in ERCP procedures with trainee involvement. Endoscopy 2023; 55: 804-811
• 5 Peng C, Nietert PJ, Cotton PB. et al. Predicting native papilla biliary cannulation success using a multinational endoscopic retrograde cholangiopancreatography (ERCP) Quality Network. BMC Gastroenterol 2013; 13: 147 DOI: 10.1186/1471-230X-13-147. (PMID: 24112846)
• 6 Jeang A, Chiang AJ. Economic and quality scheduling for effective utilization of operating rooms. J Med Syst 2012; 36: 1205-1222 DOI: 10.1007/s10916-010-9582-0. (PMID: 20814721)
• 7 Enochsson L, Thulin A, Osterberg J. et al. The Swedish registry of gallstone surgery and endoscopic retrograde cholangiopancreatography (GallRiks): A nationwide registry for quality assurance of gallstone surgery. JAMA Surg 2013; 148: 471-478 DOI: 10.1001/jamasurg.2013.1221. (PMID: 23325144)
• 8 Enochsson L, Swahn F, Arnelo U. et al. Nationwide, population-based data from 11,074 ERCP procedures from the Swedish Registry for Gallstone Surgery and ERCP. Gastrointest Endosc 2010; 72: 1175-1184
• 9 Gallriks annual reports [in Swedish]. Accessed July 16, 2024 at: www.ucr.uu.se/gallriks/for-vardgivare/rapporter/arsrapporter
• 10 Cotton PB. Fifty years of ERCP: a personal review. Gastrointest Endosc 2018; 88: 393-396 DOI: 10.1016/j.gie.2018.04.013. (PMID: 29654739)
• 11 Grigoriadis A, Morsbach F, Voulgarakis N. et al. Inter-reader agreement of interpretation of radiological course of bile duct changes between serial follow-up magnetic resonance imaging/3D magnetic resonance cholangiopancreatography of patients with primary sclerosing cholangitis. Scand J Gastroenterol 2020; 55: 228-235
• 12 Rosch T, Daniel S, Scholz M. et al. Endoscopic treatment of chronic pancreatitis: a multicenter study of 1000 patients with long-term follow-up. Endoscopy 2002; 34: 765-771
• 13 Lindberg B, Arnelo U, Bergquist A. et al. Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis. Endoscopy 2002; 34: 909-916
• 14 Ponsioen CY, Arnelo U, Bergquist A. et al. No superiority of stents vs balloon dilatation for dominant strictures in patients with primary sclerosing cholangitis. Gastroenterology 2018; 155: 752-759 e755
• 15 Arnelo U, von Seth E, Bergquist A. Prospective evaluation of the clinical utility of single-operator peroral cholangioscopy in patients with primary sclerosing cholangitis. Endoscopy 2015; 47: 696-702 DOI: 10.1055/s-0034-1391845. (PMID: 25826274)
• 16 Dumonceau JM, Tringali A, Papanikolaou IS. et al. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline – Updated October 2017. Endoscopy 2018; 50: 910-930 DOI: 10.1055/a-0659-9864. (PMID: 30086596)
• 17 Johnson G, Webster G, Boskoski I. et al. Curriculum for ERCP and endoscopic ultrasound training in Europe: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2021; 53: 1071-1087 DOI: 10.1055/a-1537-8999. (PMID: 34311472)
• 18 Halttunen J, Meisner S, Aabakken L. et al. Difficult cannulation as defined by a prospective study of the Scandinavian Association for Digestive Endoscopy (SADE) in 907 ERCPs. Scand J Gastroenterol 2014; 49: 752-758 DOI: 10.3109/00365521.2014.894120. (PMID: 24628493)
• 19 Vehvilainen S, Fagerstrom N, Valente R. et al. Single-operator peroral pancreatoscopy in the preoperative diagnostics of suspected main duct intraductal papillary mucinous neoplasms: efficacy and novel insights on complications. Surg Endosc 2022; 36: 7431-7443 DOI: 10.1007/s00464-022-09156-3. (PMID: 35277769)